uniQure N.V. (NASDAQ:QURE) Receives $37.45 Consensus Price Target from Brokerages

Key Points

• uniQure N.V. has received an average rating of "Buy" from eleven brokerage firms, with two analysts rating it as a hold, seven as buy, and two as strong buy.
• The current 12-month price target for uniQure shares averages around $37.45, while share prices have recently opened at approximately $14.84.
• In the last quarter, uniQure reported a net income loss, with a negative EPS of ($0.69) and revenue of $5.26 million, beating analyst expectations.

uniQure N.V. (NASDAQ:QURE - Get Free Report) has received an average rating of "Buy" from the eleven ratings firms that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation, seven have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $37.4545.

A number of equities research analysts have issued reports on QURE shares. Wall Street Zen upgraded uniQure from a "sell" rating to a "hold" rating in a research note on Saturday, August 2nd. Chardan Capital reiterated a "buy" rating and issued a $35.00 target price on shares of uniQure in a research note on Monday, September 8th. HC Wainwright reiterated a "buy" rating and issued a $70.00 target price on shares of uniQure in a research note on Friday, September 5th. Mizuho upgraded uniQure from a "neutral" rating to an "outperform" rating and set a $30.00 target price on the stock in a research note on Thursday, August 14th. Finally, Cantor Fitzgerald set a $47.00 target price on uniQure in a research note on Wednesday, July 30th.

uniQure Stock Performance

uniQure stock traded down $0.87 during mid-day trading on Tuesday, reaching $13.87. The company's stock had a trading volume of 2,330,082 shares, compared to its average volume of 1,115,369. The firm has a market cap of $761.05 million, a price-to-earnings ratio of -3.54 and a beta of 0.14. The business has a 50 day moving average price of $15.26 and a 200-day moving average price of $14.06. The company has a current ratio of 9.98, a quick ratio of 9.98 and a debt-to-equity ratio of 1.53. uniQure has a twelve month low of $4.45 and a twelve month high of $19.18.

uniQure (NASDAQ:QURE - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported ($0.69) EPS for the quarter, topping analysts' consensus estimates of ($0.89) by $0.20. The firm had revenue of $5.26 million during the quarter, compared to the consensus estimate of $5.00 million. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. Sell-side analysts predict that uniQure will post -3.75 EPS for the current fiscal year.

Institutional Investors Weigh In On uniQure

A number of hedge funds and other institutional investors have recently modified their holdings of QURE. Jefferies Financial Group Inc. bought a new stake in shares of uniQure during the second quarter valued at about $29,217,000. Vestal Point Capital LP raised its stake in shares of uniQure by 58.4% during the first quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company's stock valued at $50,801,000 after purchasing an additional 1,767,572 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of uniQure by 471.7% during the second quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company's stock valued at $25,199,000 after purchasing an additional 1,491,486 shares in the last quarter. Sofinnova Investments Inc. grew its holdings in uniQure by 185.5% during the second quarter. Sofinnova Investments Inc. now owns 1,558,356 shares of the biotechnology company's stock worth $21,723,000 after acquiring an additional 1,012,585 shares during the period. Finally, Aberdeen Group plc grew its holdings in uniQure by 46.8% during the first quarter. Aberdeen Group plc now owns 2,215,551 shares of the biotechnology company's stock worth $23,485,000 after acquiring an additional 706,216 shares during the period. 78.83% of the stock is currently owned by institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.